GBA1 and Parkinson disease: This observation in α-synuclein mice coupled with decreased GCase activity observed in aged and sporadic PD brains8,24,25 support the hypothesis that ambroxol is a potential disease modifying therapy for the treatment of not only PD with GBA1 mutations and GD, but also sporadic forms of PD.